SCHEMBL13320698

SCHEMBL13320698

Cc1cccc(/C=C/C(=O)Nc2ccccc2C(=O)O)n1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TRPM2 O94759 4/20 0.55
▸ LTB4R Q15722 1/20 0.55
▸ TRPA1 O75762 8/20 0.54
▸ TRPM8 Q7Z2W7 5/20 0.54
▸ MEN1 O00255 5/20 0.54
▸ KMT2A Q03164 5/20 0.54
▸ NPC1 O15118 4/20 0.54
▸ RAB9A P51151 4/20 0.54
▸ SMN1; SMN2 Q16637 4/20 0.54
▸ MAPT P10636 2/20 0.54
▸ KDM4E B2RXH2 3/20 0.53
▸ APEX1 P27695 2/20 0.53
▸ POLB P06746 2/20 0.53
▸ RECQL P46063 1/20 0.53
▸ TDP1 Q9NUW8 1/20 0.53
▸ L3MBTL1 Q9Y468 1/20 0.53
▸ ALDH1A1 P00352 2/20 0.51
▸ TP53 P04637 2/20 0.51
▸ CYP3A4 P08684 2/20 0.51
▸ HPGD P15428 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16215236 0.85 KDM4E (0.48) TRPA1TRPM8MEN1KMT2ANPC1
SCHEMBL13320688 0.84 TRPA1 (0.60) TRPM2LTB4RTRPA1TRPM8MEN1
SCHEMBL13352247 0.82 HDAC3 (0.47) MEN1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL9767884 0.81 TRPM2 (0.60) TRPM2LTB4RTRPA1TRPM8MEN1
SCHEMBL13320651 0.81 TRPM2 (0.60) TRPM2LTB4RTRPA1TRPM8MEN1
SCHEMBL294403 0.76 TRPM2 (0.83) TRPM2LTB4RTRPA1TRPM8MEN1
SCHEMBL294402 0.76 TRPM2 (0.83) TRPM2LTB4RTRPA1TRPM8MEN1
SCHEMBL15396795 0.76 TRPM2 (0.64) TRPM2LTB4RTRPA1TRPM8MEN1
SCHEMBL2781340 0.76 MEN1 (0.78) TRPM2LTB4RTRPA1TRPM8MEN1
SCHEMBL2780239 0.76 TRPA1 (0.71) TRPM2LTB4RTRPA1TRPM8MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9561201-B2 Therapeutic compounds FIBROTECH THERAPEUTICS PTY LTD (AU) 2017-02-07 — — US disclosed
US-9561201-B2 Therapeutic compounds FIBROTECH THERAPEUTICS PTY LTD (AU) 2017-02-07 — — US disclosed
US-20140357628-A1 THERAPEUTIC COMPOUNDS FIBROTECH THERAPEUTICS PTY LTD (AU) 2014-12-04 — — US disclosed
US-20140357628-A1 THERAPEUTIC COMPOUNDS FIBROTECH THERAPEUTICS PTY LTD (AU) 2014-12-04 — — US disclosed
US-8765812-B2 Therapeutic compounds FIBROTECH THERAPEUTICS PTY LTD (AU) 2014-07-01 — — US disclosed
US-8765812-B2 Therapeutic compounds FIBROTECH THERAPEUTICS PTY LTD (AU) 2014-07-01 — — US disclosed
US-20100130497-A1 Therapeutic Compounds FIBROTECH THERAPEUTICS PTY LTD (AU) 2010-05-27 — — US disclosed
WO-2008003141-A1 THERAPEUTIC COMPOUNDS FIBROTECH THERAPEUTICS PTY LTD (AU) 2008-01-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140357628-A1 THERAPEUTIC COMPOUNDS NFATC1, AADAC, NAT1 TRPM2 1034/4885LTB4R 533/4885TRPA1 78/4885
US-20100130497-A1 Therapeutic Compounds NFATC1, NAT1, AADAC TRPM2 1042/4885LTB4R 491/4885TRPA1 87/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback